HK1092722A1 - Pharmaceutical compositions and their use for manufacturing the medicament for treating atherosclerosis, dyslipidemias and related conditions - Google Patents

Pharmaceutical compositions and their use for manufacturing the medicament for treating atherosclerosis, dyslipidemias and related conditions

Info

Publication number
HK1092722A1
HK1092722A1 HK06113584.9A HK06113584A HK1092722A1 HK 1092722 A1 HK1092722 A1 HK 1092722A1 HK 06113584 A HK06113584 A HK 06113584A HK 1092722 A1 HK1092722 A1 HK 1092722A1
Authority
HK
Hong Kong
Prior art keywords
dyslipidemias
medicament
manufacturing
pharmaceutical compositions
related conditions
Prior art date
Application number
HK06113584.9A
Other languages
English (en)
Inventor
Kang Cheng
M Gerard Waters
Kathleen M Metters
Gary O'neill
Original Assignee
Merck & Co Inc
Merck Frosst Canada Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33476734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1092722(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc, Merck Frosst Canada Ltd filed Critical Merck & Co Inc
Publication of HK1092722A1 publication Critical patent/HK1092722A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/5381,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
HK06113584.9A 2003-05-15 2006-12-11 Pharmaceutical compositions and their use for manufacturing the medicament for treating atherosclerosis, dyslipidemias and related conditions HK1092722A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47066503P 2003-05-15 2003-05-15
PCT/US2004/014980 WO2004103370A1 (en) 2003-05-15 2004-05-13 Method of treating atherosclerosis, dyslipidemias and related conditions and pharmaceutical compositions

Publications (1)

Publication Number Publication Date
HK1092722A1 true HK1092722A1 (en) 2007-02-16

Family

ID=33476734

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06113584.9A HK1092722A1 (en) 2003-05-15 2006-12-11 Pharmaceutical compositions and their use for manufacturing the medicament for treating atherosclerosis, dyslipidemias and related conditions

Country Status (45)

Country Link
US (4) US20040229844A1 (hr)
EP (3) EP2286816A1 (hr)
JP (2) JP4637833B2 (hr)
KR (2) KR100960749B1 (hr)
CN (3) CN102526735A (hr)
AR (1) AR041089A1 (hr)
AU (2) AU2004240597B2 (hr)
BR (1) BRPI0410273A (hr)
CA (1) CA2525772C (hr)
CL (1) CL2004001056A1 (hr)
CO (1) CO5630034A2 (hr)
CR (2) CR8047A (hr)
CY (2) CY1109476T1 (hr)
DE (1) DE602004022036D1 (hr)
DK (2) DK2116244T3 (hr)
DO (1) DOP2004000907A (hr)
EA (2) EA009744B1 (hr)
EC (1) ECSP056156A (hr)
ES (2) ES2392743T3 (hr)
GE (2) GEP20105025B (hr)
GT (1) GT200400098A (hr)
HK (1) HK1092722A1 (hr)
HN (1) HN2004000171A (hr)
HR (2) HRP20090424T1 (hr)
IL (1) IL171962A (hr)
IS (1) IS2708B (hr)
JO (1) JO2564B1 (hr)
MA (1) MA27835A1 (hr)
ME (1) MEP60108A (hr)
MX (1) MXPA05012272A (hr)
MY (1) MY140639A (hr)
NO (1) NO20055957L (hr)
NZ (2) NZ543399A (hr)
PA (1) PA8603201A1 (hr)
PE (1) PE20050552A1 (hr)
PL (2) PL2116244T3 (hr)
PT (2) PT2116244E (hr)
RS (3) RS52731B (hr)
SG (1) SG153667A1 (hr)
SI (2) SI2116244T1 (hr)
TN (1) TNSN05290A1 (hr)
TW (2) TWI334354B (hr)
UA (1) UA89615C2 (hr)
WO (1) WO2004103370A1 (hr)
ZA (1) ZA200508288B (hr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60215000T2 (de) * 2001-05-23 2007-08-09 Merck Frosst Canada & Co, Kirkland Dihydropyrroloil[1,2-a]indol- und Tetrahydropyridol[1,2-a]indol-Derivate als Prostaglandin-D2-Rezeptor-Antagonisten
EP1603585A2 (en) * 2003-03-14 2005-12-14 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
PE20050483A1 (es) 2003-10-31 2005-08-25 Arena Pharm Inc Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas
US7019022B2 (en) * 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
LT2801354T (lt) 2004-10-08 2017-06-26 Forward Pharma A/S Kontroliuojamo atpalaidavimo farmacinės kompozicijos, apimančios fumaro rūgšties esterį
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
WO2006078776A2 (en) * 2005-01-19 2006-07-27 The Trustees Of The University Of Pennsylvania Inhibitors and methods of treatment of cardiovascular diseases, and methods for identifying inhibitors
CA2598273A1 (en) * 2005-02-17 2006-08-24 Merck & Co., Inc. Method of treating atherosclerosis, dyslipidemias and related conditions
JP2008538277A (ja) * 2005-02-18 2008-10-23 アリーナ ファーマシューティカルズ, インコーポレイテッド 脂質関連障害の治療用の組成物および方法
WO2006124490A2 (en) * 2005-05-17 2006-11-23 Schering Corporation Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US7750015B2 (en) * 2005-05-17 2010-07-06 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
JP2009507791A (ja) * 2005-08-29 2009-02-26 メルク エンド カムパニー インコーポレーテッド ナイアシン受容体アゴニスト、このような化合物を含有する組成物、および治療方法
CA2620864A1 (en) * 2005-09-01 2007-03-08 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
WO2007042035A2 (en) * 2005-10-07 2007-04-19 Aditech Pharma Ab Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
CA2634940A1 (en) * 2005-12-21 2007-07-05 Schering Corporation Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and h3 receptor antagonist/inverse agonist
BRPI0620386A2 (pt) * 2005-12-21 2011-12-20 Schering Corp composição compreendendo a combinação de um antagonista de h3/agonista inverso e um supressor de apetite e uso da referida composição
JP2009525961A (ja) * 2006-01-20 2009-07-16 シェーリング コーポレイション 異常脂質血症の処置のためのニコチン酸受容体アゴニストとしての複素環
US20090069275A1 (en) * 2006-02-17 2009-03-12 Rocca Jose G Low flush niacin formulation
CA2663502A1 (en) * 2006-09-15 2008-03-20 Schering Corporation Azetidinone derivatives and methods of use thereof
US20080076750A1 (en) * 2006-09-15 2008-03-27 Aslanian Robert G Azetidinone Derivatives and Methods of Use Thereof
MX2009002924A (es) 2006-09-15 2009-05-28 Schering Corp Derivados de azetidinona espirociclica para el tratamiento de trastornos del metabolismo de los lipidos, el dolor, la diabetes y otros trastornos.
WO2008039882A1 (en) * 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc A combination of niacin and a prostaglandin d2 receptor antagonist
US20100260841A1 (en) * 2007-02-08 2010-10-14 Paolini John F Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions
US20090076117A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched laropiprant
CN101559058B (zh) * 2008-04-16 2011-07-20 北京本草天源药物研究院 一种治疗血脂异常的药物组合物
EP2303327A2 (en) * 2008-05-20 2011-04-06 Cerenis Therapeutics S.A. Niacin and nsaid for combination therapy
US8507473B2 (en) 2008-09-11 2013-08-13 Arena Pharmaceuticals, Inc. 3H-imidazo[4,5-b]pyridin-5-ol derivatives useful in the treatment of GPR81 receptor disorders
EP2341773A4 (en) * 2008-09-24 2012-03-07 Merck Sharp & Dohme PHARMACEUTICAL COMPOSITIONS FROM ATORVASTATIN
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
US8906420B2 (en) 2009-01-09 2014-12-09 Forward Pharma A/S Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
BR112012023039A2 (pt) 2010-03-16 2016-05-17 Aventis Pharma Inc pirimidina substituída como um antagonista de receptor prostaglandina d2
MX2012010035A (es) 2010-03-16 2012-10-01 Aventis Pharma Inc Pirimidinas sustituidas como antagonistas del receptor de la prostaglandina d2.

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3535326A (en) * 1967-03-06 1970-10-20 Sumitomo Chemical Co Certain tetrahydro carboline derivatives
BE787444A (fr) * 1971-08-13 1973-02-12 Hoffmann La Roche Composes polycycliques
US4009181A (en) * 1973-01-22 1977-02-22 Hoffmann-La Roche Inc. Cyclopenta[b]indole-2-carboxylic acids and derivatives thereof
US4057559A (en) * 1973-10-01 1977-11-08 American Home Products Corporation Carbazole acetic acid derivatives
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
GB2076242B (en) 1977-09-30 1982-10-20 Rca Corp Television system scheduler
US4342767A (en) 1980-01-23 1982-08-03 Merck & Co., Inc. Hypocholesteremic fermentation products
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US5021447A (en) * 1986-01-23 1991-06-04 Merck Frosst Canada, Inc. Tetrahydrocarbazole 1-alkanoic acids and pharmaecutical compositions
US4808608A (en) * 1986-01-23 1989-02-28 Merck & Co., Inc. Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use
US4940719A (en) * 1986-03-27 1990-07-10 Merck Frosst Canada, Inc. Tetrahydrocarbazole esters, pharmaceutical compositions and use
US4775680A (en) * 1987-07-21 1988-10-04 Merck & Co., Inc. Cyclohept[b]indolealkanoic acids, pharmaceutical compositions and use
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
US5190972A (en) * 1992-01-27 1993-03-02 The University Of Melbourne Method of combatting cyclosporine organ toxicity with prostaglandin analogs
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
CA2218696A1 (en) * 1995-04-19 1996-10-24 L. Jackson Ii Roberts Compositions, kits and methods for administration of antilipemic and an ti-platelet aggregation drugs
ATE219495T1 (de) 1995-10-31 2002-07-15 Schering Corp Zuckersubstituierte 2-azetidinone, verwendbar als hypocholesterdenische arzneimittel
WO1997016424A1 (en) 1995-11-02 1997-05-09 Schering Corporation Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-([phenyl or 4-fluorophenyl])-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinone
PT814782E (pt) 1995-12-22 2003-04-30 Nissan Chemical Ind Ltd Composicao farmaceutica estabilizada com um agente basico
US5739321A (en) 1996-05-31 1998-04-14 Schering Corporation 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
US5886171A (en) 1996-05-31 1999-03-23 Schering Corporation 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
US5756470A (en) 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
US6469035B1 (en) * 1997-07-31 2002-10-22 Eugenio A. Cefali Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid
US20010006644A1 (en) * 1997-07-31 2001-07-05 David J. Bova Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
DE69837610T2 (de) * 1997-07-31 2008-01-03 Kos Life Sciences, Inc., Weston Manteltablette enthaltend nikotinsäure oder einen stoff, der zu nikotinsäure metabolisiert wird in verzögert freigesetzter form und einen hmg-coa reduktasehemmer im mantel zur sofortigen freisetzung
AU752059B2 (en) * 1997-10-27 2002-09-05 Dr. Reddy's Laboratories Limited Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them
US6133001A (en) 1998-02-23 2000-10-17 Schering Corporation Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(R)-[3(S)-Hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4 -hydroxyphenyl)-2-azetidinone
US5919672A (en) 1998-10-02 1999-07-06 Schering Corporation Resolution of trans-2-(alkoxycarbonylethyl)-lactams useful in the synthesis of 1-(4-fluoro-phenyl)-3(R)- (S)-hydroxy-3-(4-fluorophenyl)-propyl!-4(S)-(4-hydroxyphenyl)-2-azetidinone
ATE297892T1 (de) 1998-12-07 2005-07-15 Schering Corp Verfahren zur herstellung von azetidinonen
AU779264B2 (en) 1998-12-23 2005-01-13 G.D. Searle Llc Combinations for cardiovascular indications
EP2281899A3 (en) 1999-04-05 2012-01-04 Schering Corporation Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(R)-3(S)-hydroxy-3-(4-fluorophenyl)propyl)-4(S)-(4-hydroxyphenyl)-2-azetidinone
US6593078B1 (en) 1999-04-16 2003-07-15 Schering Corporation Use of azetidinone compounds
IT1306141B1 (it) * 1999-05-17 2001-05-30 Giampiero Valletta Composizione per il trattamento del prurito uremico e di forme diprurito non riconducibili a lesioni organiche.
CA2402174A1 (en) 2000-03-09 2001-09-13 Ono Pharmaceutical Co., Ltd. Indole derivatives, process for preparation of the same and use thereof
US20010047027A1 (en) 2000-04-12 2001-11-29 Marc Labelle Prostaglandin D2 receptor antagonists
JP2002008186A (ja) * 2000-06-23 2002-01-11 Mitsubishi Heavy Ind Ltd 車種識別装置
US6410583B1 (en) 2000-07-25 2002-06-25 Merck Frosst Canada & Co. Cyclopentanoindoles, compositions containing such compounds and methods of treatment
JP3889563B2 (ja) * 2000-09-13 2007-03-07 三洋電機株式会社 映像信号処理回路
AU2002242910A1 (en) 2001-04-11 2002-10-28 Glaxo Group Limited Medicaments which are modulators of hm74 and/or hm74a activity
DE60215000T2 (de) * 2001-05-23 2007-08-09 Merck Frosst Canada & Co, Kirkland Dihydropyrroloil[1,2-a]indol- und Tetrahydropyridol[1,2-a]indol-Derivate als Prostaglandin-D2-Rezeptor-Antagonisten
CA2459515A1 (en) 2001-09-07 2003-03-20 Kazuhiko Torisu Indole derivatives
AR038136A1 (es) * 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
BR0308518A (pt) 2002-03-19 2005-02-22 Ono Pharmaceutical Co Compostos ácidos carboxìlicos e drogas contendo os compostos como o ingrediente ativo
MXPA04012149A (es) * 2002-06-03 2005-04-19 Novartis Ag El uso de cianopirrolidinas sustituidas y prepraraciones de combinacion que las contienen para tratar hiperlipidemia y enfermedades asociadas.
US7019022B2 (en) * 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
JP4129960B2 (ja) * 2005-07-01 2008-08-06 タキゲン製造株式会社 ステー

Also Published As

Publication number Publication date
PT1624871E (pt) 2009-09-07
CY1113342T1 (el) 2016-06-22
EA200702674A1 (ru) 2008-04-28
MXPA05012272A (es) 2006-05-19
CR9808A (es) 2008-07-29
CN101559227B (zh) 2012-03-21
HN2004000171A (es) 2011-07-11
SI2116244T1 (sl) 2012-12-31
TWI334354B (en) 2010-12-11
CN102526735A (zh) 2012-07-04
CR8047A (es) 2006-07-14
NO20055957L (no) 2006-02-14
NZ572515A (en) 2010-07-30
US20110118292A1 (en) 2011-05-19
GEP20105025B (en) 2010-06-25
CA2525772C (en) 2011-03-15
MY140639A (en) 2010-01-15
TNSN05290A1 (en) 2007-07-10
RS20120498A1 (en) 2013-08-30
JO2564B1 (en) 2010-11-03
NZ543399A (en) 2009-02-28
CN1787819A (zh) 2006-06-14
EP1624871B1 (en) 2009-07-15
KR100806008B1 (ko) 2008-02-26
JP2006526030A (ja) 2006-11-16
SG153667A1 (en) 2009-07-29
MA27835A1 (fr) 2006-04-03
IL171962A0 (en) 2006-04-10
KR20080003470A (ko) 2008-01-07
US20090233977A1 (en) 2009-09-17
GEP20084569B (en) 2008-12-25
AU2004240597B2 (en) 2011-01-06
GT200400098A (es) 2005-03-03
DOP2004000907A (es) 2004-11-30
AU2004240597A1 (en) 2004-12-02
AR041089A1 (es) 2005-05-04
JP2010077151A (ja) 2010-04-08
SI1624871T1 (sl) 2009-12-31
IS2708B (is) 2011-01-15
PL1624871T3 (pl) 2009-12-31
RS52731B (sr) 2013-08-30
IL171962A (en) 2012-06-28
RS20120499A1 (en) 2013-08-30
HRP20090424T1 (hr) 2009-09-30
PE20050552A1 (es) 2005-08-06
ECSP056156A (es) 2006-04-19
HRP20120818T1 (hr) 2012-11-30
US20040229844A1 (en) 2004-11-18
ES2392743T3 (es) 2012-12-13
EP1624871A1 (en) 2006-02-15
TWI341199B (en) 2011-05-01
TW200503757A (en) 2005-02-01
PL2116244T3 (pl) 2013-01-31
AU2011200986B2 (en) 2012-11-08
ZA200508288B (en) 2008-08-27
DK1624871T3 (da) 2009-11-16
KR100960749B1 (ko) 2010-06-01
CN101559227A (zh) 2009-10-21
CL2004001056A1 (es) 2005-03-28
KR20060012617A (ko) 2006-02-08
PA8603201A1 (es) 2005-02-04
EP2116244A1 (en) 2009-11-11
DK2116244T3 (da) 2012-11-26
RS20050777A (sr) 2008-04-04
EP2116244B1 (en) 2012-08-08
TW200803844A (en) 2008-01-16
AU2011200986A1 (en) 2011-03-31
EA011895B1 (ru) 2009-06-30
EP2286816A1 (en) 2011-02-23
US20100076002A1 (en) 2010-03-25
CO5630034A2 (es) 2006-04-28
MEP60108A (hr) 2011-05-10
DE602004022036D1 (de) 2009-08-27
CA2525772A1 (en) 2004-12-02
EA200501817A1 (ru) 2006-06-30
ES2328148T3 (es) 2009-11-10
UA89615C2 (ru) 2010-02-25
PT2116244E (pt) 2012-11-02
BRPI0410273A (pt) 2006-05-16
CN100441184C (zh) 2008-12-10
JP4637833B2 (ja) 2011-02-23
CY1109476T1 (el) 2014-08-13
EA009744B1 (ru) 2008-04-28
WO2004103370A1 (en) 2004-12-02
IS8071A (is) 2005-10-13

Similar Documents

Publication Publication Date Title
HK1092722A1 (en) Pharmaceutical compositions and their use for manufacturing the medicament for treating atherosclerosis, dyslipidemias and related conditions
IL213597A0 (en) Compounds, pharmaceutical compositions comprising them and their use in the manufacture of medicaments
IL178079A (en) History of phenyl 1-phenyl-4,3,2,1-tetrahydro-beta-carboline-2-carboxylate and medicinal preparations containing them
GB0320382D0 (en) Pharmaceutical compositions
GB0327723D0 (en) Pharmaceutical compositions
IL170758A0 (en) 7-amino-isoindolyl compounds and their pharmaceutical uses
IL174479A (en) The derivatives of myastrin, pharmaceutical preparations containing them and their uses
IL175245A0 (en) Thiozolidinones, production and use thereof as medicaments
ZA200605080B (en) Pharmaceutical compositions
GB0300531D0 (en) Pharmaceutical compositions
EP1648411A4 (en) PHARMACEUTICAL COMPOSITIONS
PL394604A1 (pl) Pochodna winyloazacykloalkanowa, jej zastosowanie oraz kompozycja farmaceutyczna
IL181216A0 (en) 3, 5-seco-4-norcholestane derivatives and pharmaceutical compositions containing the same
HK1093896A1 (en) Medicinal composition
AP2006003557A0 (en) Antimalarial compositions and process thereof.
IL173918A0 (en) Substituted thienoimidazoles, method for production and use thereof as medicament or diagnostic and medicaments comprising the same
EP1655029A4 (en) MEDICINAL COMPOSITIONS
EP1600445A4 (en) CURATIVE PREPARATION
GB0308968D0 (en) Medicaments
GB0314733D0 (en) Medicaments
EP1711490A4 (en) P-GLYCOPROTEIN INHIBITOR, PREPARATION METHOD, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
HU0304095D0 (en) Novel, effective pharmaceutical compositions
IL191560A0 (en) 3,4-dihydrobenzoxazine derivatives and pharmaceutical compositions containing the same
GB0305579D0 (en) Pharmaceutical compositions
GB0309509D0 (en) Pharmaceutical compositions and their uses

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20140513